Concepedia

Author

Alan K. Burnett

Cardiff UniversityORCID

Also Known As

A Burnett, A K Burnett, A. BURNETT, A. Burnett, A. K. BURNETT, A. K. Burnett, A.K. BURNETT, A.K. Burnett, ALAN BURNETT, Alan Burnett

599

Publications

35.9K

Citations

81

H-Index

125

Concepts

All Affiliations

Cardiff UniversityUniversity College LondonUniversity of WalesUniversity of BirminghamUniversity Hospital of Wales
AK

About

Alan K. Burnett is an author at Cardiff University specializing in medicine, hematology, and oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

37

70

6.2K

2

Health Sciences

21

27

2.9K

3

Public Health

2

2

38

4

Engineering

1

1

140

5

Natural Sciences

1

1

18

Alan K. Burnett

×

200

Publications

27.2K

Citations

76

H-Index

YearCitations

The Importance of Diagnostic Cytogenetics on Outcome in AML: Analysis of 1,612 Patients Entered Into the MRC AML 10 Trial

David Grimwade, Helen M. Walker, Fiona Oliver,

Blood

1998

2.6K

Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials

David Grimwade, Robert K. Hills, Anthony V. Moorman,

Blood

2010

1.9K

The presence of a FLT3 internal tandem duplication in patients with acute myeloid leukemia (AML) adds important prognostic information to cytogenetic risk group and response to the first cycle of chemotherapy: analysis of 854 patients from the United Kingdom Medical Research Council AML 10 and 12 trials

Panagiotis Kottaridis, Rosemary E. Gale, Marion E. Frew,

Blood

2001

1.5K

Acute Myeloid Leukemia

Bob Löwenberg, James R. Downing, Alan K. Burnett

New England Journal of Medicine

1999

1.2K

Assessment of Minimal Residual Disease in Standard-Risk AML

Adam Ivey, Robert K. Hills, Michael A. Simpson,

New England Journal of Medicine

2016

812

In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993)

Anthony H. Goldstone, Susan Richards, Hillard M. Lazarus,

Blood

2007

780

The impact of FLT3 internal tandem duplication mutant level, number, size, and interaction with NPM1 mutations in a large cohort of young adult patients with acute myeloid leukemia

Rosemary E. Gale, Claire Green, Christopher Allen,

Blood

2007

739

Identification of Patients With Acute Myeloblastic Leukemia Who Benefit From the Addition of Gemtuzumab Ozogamicin: Results of the MRC AML15 Trial

Alan K. Burnett, Robert K. Hills, Donald Milligan,

Journal of Clinical Oncology

2010

644

A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

Alan K. Burnett, Donald Milligan, Archie Prentice,

Cancer

2007

613

Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial

Alan K. Burnett, Anthony H. Goldstone, Richard MF Stevens,

The Lancet

1998

565

Page 1